Replies to post #102819 on Biotech Values

[jq1234]

After watching the Bevacizumab breast cancer ODAC, I walked away with only one conclusion that is the "new" Genentech oncology and its relationship with FDA can each be described with one word - incompetent and hostile, respectively.

Spot on. I cringed when I first read Roche's horrendous performance, in public, I have to add, after Avastin MBC ODAC at Pharmalot.

http://www.pharmalot.com/2010/07/roche-exec-fda-stacked-the-deck-against-avastin/

I was immediately worried about T-DM1 filing. We might never know if Roche tried to pin FDA to a corner with T-DM1 filing.